In Vivo Efficacy of Cefiderocol against Ceftolozane/Tazobactam- and Ceftazidime/Avibactam-Resistant Pseudomonas Aeruginosa Carrying the AmpC E219K Substitution
| UDC.coleccion | Investigación | |
| UDC.departamento | Medicina | |
| UDC.grupoInv | Investigación en Microbiología (INIBIC) | |
| UDC.institutoCentro | INIBIC - Instituto de Investigacións Biomédicas de A Coruña | |
| UDC.issue | 10 | |
| UDC.journalTitle | Antimicrobial Agents and Chemotherapy | |
| UDC.startPage | e0072426 | |
| UDC.volume | 70 | |
| dc.contributor.author | Rodríguez-Coello, Arianna | |
| dc.contributor.author | Outeda-García, Michelle | |
| dc.contributor.author | García-Pose, Andrea | |
| dc.contributor.author | González-Pinto, Lucía | |
| dc.contributor.author | Báez-Barroso, Gabriela Alejandra | |
| dc.contributor.author | Guijarro-Sánchez, Paula | |
| dc.contributor.author | Muras, Andrea | |
| dc.contributor.author | Taltavull, Biel | |
| dc.contributor.author | Fraile-Ribot, Pablo Arturo | |
| dc.contributor.author | Alonso-García, Isaac | |
| dc.contributor.author | Oliver, Antonio | |
| dc.contributor.author | Vázquez-Ucha, Juan Carlos | |
| dc.contributor.author | Arca-Suárez, Jorge | |
| dc.contributor.author | Bou, Germán | |
| dc.contributor.author | Beceiro Casas, Alejandro | |
| dc.date.accessioned | 2026-10-19T07:04:55Z | |
| dc.date.available | 2026-10-19T07:04:55Z | |
| dc.date.issued | 2026-09-16 | |
| dc.description | Brief report | |
| dc.description.abstract | [Abstract] Chromosomal AmpC variants selected during ceftolozane/tazobactam or ceftazidime/avibactam therapy may affect cefiderocol activity. We evaluated the impact of the E219K substitution on cefiderocol efficacy using isogenic Pseudomonas aeruginosa pairs in a murine bacteremia model. Cefiderocol achieved greater bacterial reductions in parental isolates than in E219K derivatives, despite susceptible MICs. Cefiderocol failed to achieve stasis against a cefiderocol-resistant isolate. E219K impaired cefiderocol efficacy in vivo, supporting close monitoring of cefiderocol activity against isolates carrying this variant. | |
| dc.description.sponsorship | This research was supported by projects PI23/00851 awarded to A.B., PI24/00920 awarded to G.B., and PI22/01212 and PI25/00116 awarded to J.A.-S. that were all funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. The research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (CB21/13/00055 and CB21/13/00099), Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU by project IN607D 2024/008 to J.A.-S. (GAIN-Agencia Gallega de Innovación, Consellería de Economía, Emprego e Industria), and "Axudas para a consolidación de grupos de investigación" (IN607A 2024/09 to G.B. and IN607D 2024/08 to J.A.-S.). J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 (GAIN-Xunta de Galicia). P.G.-S. was financially supported by grant IN606A 2021/021 (Xunta de Galicia). M.O.-G. was financially supported by IN606A 2023/023 (GAIN-Xunta de Galicia). I.A.-G. was financially supported by the Juan Rodés (ISCIII, JR23/00036). G.A.B.-B. was financially supported by IN606A-2024/033. A.R.-C. was financially supported by the FI24/00178 (ISCIII). A.M. was supported by CD23/00057 (ISCIII). L.G.-P. was supported by FI23/00074 (ISCIII). A.G.-P was financially supported by FPU24/02755 (Ministerio de Ciencia, Innovación y Universidades) and IN606A-2025/034 (GAIN-Xunta de Galicia). | |
| dc.identifier.citation | Rodríguez-Coello A, Outeda-García M, García-Pose A, Gonzalez-Pinto L, Báez-Barroso GA, Guijarro-Sánchez P, Muras A, Taltavull B, Fraile-Ribot P, Alonso-Garcia I, Oliver A, Vázquez-Ucha JC, Arca-Suárez J, Bou G, Beceiro A. In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution. Antimicrob Agents Chemother. 2026 Oct 7;70(10):e0072426. | |
| dc.identifier.doi | 10.1128/aac.00724-26 | |
| dc.identifier.issn | 0066-4804 | |
| dc.identifier.uri | https://hdl.handle.net/2183/49822 | |
| dc.language.iso | eng | |
| dc.publisher | American Society for Microbiology | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI23%2F00851/ES/Actividad in vivo de nuevos inhibidores de carbapenemasas frente a patógenos críticos multirresistentes: K. pneumoniae productor de carbapenemasas y P. aeruginosa./ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI24%2F00920/ES/Vacunas versátiles basadas en ARN para combatir las infecciones causadas por cepas multirresistentes de Pseudomonas aeruginosa/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI22%2F01212/ES/Inhibidores de carbapenemasas: actividad frente a Enterobacterales productores de carbapenemasas, mecanismos e impacto en la evolución de la resistencia antimicrobiana (PROTECT)/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2024-2027/PI25%2F00116/ES/Medicina personalizada frente a Gram negativos prioritarios: posicionamiento de nuevos ß-lactámicos, evolución dirigida del resistoma y diagnóstico de precisión con MALDI-TOF y machine learning/ | |
| dc.relation.uri | https://doi.org/10.1128/aac.00724-26 | |
| dc.rights | Attribution 4.0 International | en |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | E219K | |
| dc.subject | PDC | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.subject | Cefiderocol | |
| dc.subject | Ceftazidime/avibactam; | |
| dc.subject | Ceftolozane/tazobactam | |
| dc.subject | Murine infection | |
| dc.title | In Vivo Efficacy of Cefiderocol against Ceftolozane/Tazobactam- and Ceftazidime/Avibactam-Resistant Pseudomonas Aeruginosa Carrying the AmpC E219K Substitution | |
| dc.type | journal article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea | |
| relation.isAuthorOfPublication.latestForDiscovery | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea |

